The ORR for patients with NSCLC with a molecular alteration of interest was 13.2%, which is lower than that reported for next-generation therapies selectively targeting a single kinase, such as MET or RET [11, 12]. This evidence concerns the gene RET and non-small cell lung carcinoma.